chr3:119499331:> Detail (hg19)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr3:119,499,331-119,537,334 |
| hg38 | chr3:119,780,484-119,818,487 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| <0.001 | squamous cell carcinoma | PAR-2 was immunolocalized in oral SCC and carcinoma in situ cells, especially in... | BeFree | 25912757 | Detail |
| <0.001 | Cardiovascular Diseases | NA | BeFree | Detail | |
| <0.001 | CNS disorder | NA | BeFree | Detail | |
| <0.001 | Primary biliary cirrhosis | NA | BeFree | Detail | |
| 0.003 | Cholangitis, Sclerosing | NA | BeFree,GAD | Detail | |
| 0.001 | cholestasis | The in vivo experiments using PXR siRNA revealed that Tan IIA could protect agai... | BeFree | 25660334 | Detail |
| 0.003 | intrahepatic cholestasis | NA | LHGDN | Detail | |
| <0.001 | colitis | In UC, pancolitis (but not exclusively left-sided colitis) was associated with a... | BeFree | 24965812 | Detail |
| 0.010 | ulcerative colitis | NA | BeFree,GAD,LHGDN | Detail | |
| 0.001 | Colonic Neoplasms | NA | BeFree | Detail | |
| 0.002 | colorectal carcinoma | NA | BeFree | Detail | |
| <0.001 | Coronary Arteriosclerosis | NA | BeFree | Detail | |
| <0.001 | Coronary heart disease | NA | BeFree | Detail | |
| <0.001 | craniosynostosis | NA | BeFree | Detail | |
| 0.007 | Crohn Disease | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | cystic fibrosis | NA | BeFree | Detail | |
| 0.002 | Deafness | NA | GAD | Detail | |
| <0.001 | Presenile dementia | NA | BeFree | Detail | |
| <0.001 | Dermatitis, Atopic | NA | BeFree | Detail | |
| <0.001 | Diabetes | NA | BeFree | Detail | |
| 0.121 | diabetes mellitus | NA | BeFree,CTD_human | Detail | |
| <0.001 | Diabetes Mellitus, Non-Insulin-Dependent | NA | BeFree | Detail | |
| <0.001 | Diabetic Nephropathy | NA | BeFree | Detail | |
| <0.001 | diarrhea | NA | BeFree | Detail | |
| 0.002 | Dwarfism | NA | BeFree | Detail | |
| <0.001 | Eczema | NA | BeFree | Detail | |
| <0.001 | Experimental Autoimmune Encephalomyelitis | NA | BeFree | Detail | |
| 0.003 | Endometrial Neoplasms | NA | LHGDN | Detail | |
| <0.001 | endometriosis | NA | BeFree | Detail | |
| 0.003 | epilepsy | NA | BeFree,GAD | Detail | |
| 0.120 | Esophageal Neoplasms | Here, we used reverse transcription-PCR (RT-PCR) and western blot to detect prot... | BeFree,CTD_human | 25297082 | Detail |
| 0.120 | Fatty Liver | NA | BeFree,CTD_human | Detail | |
| <0.001 | gastroesophageal reflux disease | NA | BeFree | Detail | |
| <0.001 | Gastrointestinal Diseases | NA | BeFree | Detail | |
| <0.001 | glioblastoma | NA | BeFree | Detail | |
| <0.001 | Glioma | NA | BeFree | Detail | |
| <0.001 | Hay fever | NA | BeFree | Detail | |
| 0.002 | Head and Neck Neoplasms | NA | GAD | Detail | |
| 0.002 | Hearing Loss, Partial | NA | GAD | Detail | |
| <0.001 | Heart failure | NA | BeFree | Detail | |
| <0.001 | congestive heart failure | NA | BeFree | Detail | |
| <0.001 | hepatitis | NA | BeFree | Detail | |
| <0.001 | hepatitis B | NA | BeFree | Detail | |
| 0.120 | Hepatomegaly | NA | CTD_human | Detail | |
| 0.003 | HIV Infections | NA | BeFree,GAD | Detail | |
| <0.001 | Hyperalgesia | NA | BeFree | Detail | |
| <0.001 | pulmonary hypertension | NA | BeFree | Detail | |
| <0.001 | hypothyroidism | NA | BeFree | Detail | |
| 0.001 | Immune System Diseases | NA | BeFree | Detail | |
| 0.120 | Female infertility | NA | CTD_human | Detail | |
| 0.009 | Inflammatory Bowel Diseases | Artemisinin protects against dextran sulfate-sodium-induced inflammatory bowel d... | BeFree,GAD | 24886881 | Detail |
| 0.009 | Inflammatory Bowel Diseases | Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregna... | BeFree,GAD | 25472953 | Detail |
| 0.007 | Crohn Disease | Genomic DNA from 2823 individuals of Caucasian origin including 859 patients wit... | BeFree | 21830270 | Detail |
| <0.001 | influenza | NA | BeFree | Detail | |
| <0.001 | irritable bowel syndrome | NA | BeFree | Detail | |
| <0.001 | ischemia | NA | BeFree | Detail | |
| 0.120 | neonatal jaundice | NA | BeFree,CTD_human | Detail | |
| <0.001 | Keloid | NA | BeFree | Detail | |
| <0.001 | leishmaniasis | NA | BeFree | Detail | |
| <0.001 | leukemia | NA | BeFree | Detail | |
| <0.001 | chronic lymphocytic leukemia | NA | BeFree | Detail | |
| 0.003 | Leukemia, Myelocytic, Acute | NA | BeFree,GAD | Detail | |
| <0.001 | Myeloid Leukemia, Chronic | Hence, agonists for PXR, RAR and RXR may be potentially used to improve the effi... | BeFree | 25039279 | Detail |
| 0.003 | leukopenia | NA | BeFree,GAD | Detail | |
| 0.003 | liver cirrhosis | NA | BeFree,GAD | Detail | |
| <0.001 | Liver diseases | NA | BeFree | Detail | |
| 0.001 | Liver neoplasms | NA | BeFree | Detail | |
| <0.001 | Lung diseases | NA | BeFree | Detail | |
| <0.001 | Chronic Obstructive Airway Disease | NA | BeFree | Detail | |
| 0.001 | Lung Neoplasms | NA | BeFree | Detail | |
| <0.001 | Lupus Vulgaris | NA | BeFree | Detail | |
| <0.001 | Lupus Erythematosus, Discoid | NA | BeFree | Detail | |
| 0.001 | Lupus Erythematosus, Systemic | NA | BeFree | Detail | |
| <0.001 | lymphoma | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of stomach | NA | BeFree | Detail | |
| <0.001 | medulloblastoma | Coagulation pathway sensors (F3/TF, F2R/PAR-1) are expressed in MB in a subtype-... | BeFree | 25163932 | Detail |
| <0.001 | Mesothelioma | The role of PAR1 in mesothelioma progression is just emerging and our observatio... | BeFree | 25364818 | Detail |
| <0.001 | Metabolic Diseases | Nuclear hormone receptors PXR and CAR and metabolic diseases. | BeFree | 25390021 | Detail |
| <0.001 | Metabolic Diseases | Overall, our results uncover SLC13A5 as a novel target gene of PXR and may contr... | BeFree | 25628225 | Detail |
| <0.001 | multiple myeloma | NA | BeFree | Detail | |
| <0.001 | multiple sclerosis | NA | BeFree | Detail | |
| <0.001 | Mycoses | Research undertaken over the last decade has uncovered critical roles of CD5L as... | BeFree | 26048980 | Detail |
| 0.003 | myocardial infarction | NA | BeFree,GAD | Detail | |
| <0.001 | myocarditis | NA | BeFree | Detail | |
| 0.005 | Neoplasm Metastasis | Low PXR expression has been shown to promote tumor initiation and metastasis. | BeFree | 25268617 | Detail |
| 0.002 | Neoplasm Recurrence, Local | NA | GAD | Detail | |
| <0.001 | neuroblastoma | NA | BeFree | Detail | |
| 0.005 | neutropenia | NA | BeFree,GAD | Detail | |
| 0.121 | obesity | NA | BeFree,CTD_human | Detail | |
| 0.001 | Degenerative polyarthritis | NA | BeFree | Detail | |
| <0.001 | osteoporosis | NA | BeFree | Detail | |
| 0.002 | Osteoporosis, Postmenopausal | NA | GAD | Detail | |
| 0.123 | osteosarcoma | NA | BeFree,CTD_human,LHGDN | Detail | |
| <0.001 | ovarian carcinoma | NA | BeFree | Detail | |
| <0.001 | Pain | The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV... | BeFree | 24779362 | Detail |
| <0.001 | Pain | PAR-2 activation may modulate these responses through adenosine triphosphate (AT... | BeFree | 26294672 | Detail |
| <0.001 | Pancreatic Neoplasm | NA | BeFree | Detail | |
| <0.001 | Peutz-Jeghers syndrome | NA | BeFree | Detail | |
| <0.001 | pneumonia | NA | BeFree | Detail | |
| <0.001 | Prader-Willi syndrome | NA | BeFree | Detail | |
| 0.002 | Pregnancy Complications | NA | GAD | Detail | |
| <0.001 | Prostatic Neoplasms | NA | BeFree | Detail | |
| <0.001 | Pruritus | NA | BeFree | Detail | |
| <0.001 | psoriasis | NA | BeFree | Detail | |
| <0.001 | Psychotic Disorders | NA | BeFree | Detail | |
| <0.001 | pulmonary edema | NA | BeFree | Detail | |
| <0.001 | pulmonary emphysema | NA | BeFree | Detail | |
| <0.001 | pulmonary fibrosis | NA | BeFree | Detail | |
| <0.001 | rhabdomyosarcoma | NA | BeFree | Detail | |
| <0.001 | Seizures | NA | BeFree | Detail | |
| <0.001 | Septicemia | NA | BeFree | Detail | |
| <0.001 | Dermatologic disorders | NA | BeFree | Detail | |
| <0.001 | Skin Neoplasms | NA | BeFree | Detail | |
| <0.001 | Spinal Cord Diseases | NA | BeFree | Detail | |
| 0.002 | Tobacco use disorder | NA | GAD | Detail | |
| <0.001 | Turner syndrome | NA | BeFree | Detail | |
| <0.001 | Virus Diseases | NA | BeFree | Detail | |
| <0.001 | severe combined immunodeficiency | NA | BeFree | Detail | |
| 0.002 | Neoplasms, Second Primary | NA | GAD | Detail | |
| <0.001 | antiphospholipid syndrome | NA | BeFree | Detail | |
| <0.001 | Polyendocrinopathies, Autoimmune | NA | BeFree | Detail | |
| 0.120 | hypophosphatemia | NA | CTD_human | Detail | |
| <0.001 | Carcinoma of lip | NA | BeFree | Detail | |
| <0.001 | Hepatic necrosis | NA | BeFree | Detail | |
| <0.001 | Arterial thrombosis | NA | BeFree | Detail | |
| <0.001 | esophageal carcinoma | Regarding TE-1 and TE-10 protein expression, we found that in randomized esophag... | BeFree | 25297082 | Detail |
| <0.001 | Joint swelling | NA | BeFree | Detail | |
| <0.001 | Idiopathic pulmonary hypertension | NA | BeFree | Detail | |
| <0.001 | Madelung Deformity | NA | BeFree | Detail | |
| <0.001 | Lipid Metabolism Disorders | NA | BeFree | Detail | |
| <0.001 | Cicatrix, Hypertrophic | NA | BeFree | Detail | |
| 0.001 | Tumor Progression | NA | BeFree | Detail | |
| <0.001 | cholangiocarcinoma | NA | BeFree | Detail | |
| <0.001 | Inflammatory pain | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of female breast | NA | BeFree | Detail | |
| 0.001 | pancreatic carcinoma | NA | BeFree | Detail | |
| <0.001 | Fibrosis, Liver | NA | BeFree | Detail | |
| <0.001 | Dyslipidemias | NA | BeFree | Detail | |
| 0.003 | Malignant neoplasm of lung | A functional polymorphism in the 3'-UTR of PXR interacts with smoking to increas... | BeFree,GAD | 25268617 | Detail |
| 0.003 | Malignant neoplasm of lung | Recently, PRR(L) was reported to enhance proliferation of breast and lung cancer... | BeFree,GAD | 26058814 | Detail |
| <0.001 | Proliferative vitreoretinopathy | The purpose of this study was to identify interacting signaling pathways by whic... | BeFree | 26247679 | Detail |
| <0.001 | Sepsis | NA | BeFree | Detail | |
| <0.001 | carotid artery occlusion | NA | BeFree | Detail | |
| 0.003 | Leri-Weill dyschondrosteosis | NA | BeFree | Detail | |
| <0.001 | Chronic Periodontitis | NA | BeFree | Detail | |
| <0.001 | Cholestasis of pregnancy | NA | BeFree | Detail | |
| <0.001 | gray platelet syndrome | NA | BeFree | Detail | |
| <0.001 | Disease due to Parvoviridae | NA | BeFree | Detail | |
| <0.001 | Carcinoma breast stage IV | NA | BeFree | Detail | |
| <0.001 | Metastatic melanoma | The present finding uncovers a novel role of MDA-9/syntenin as an important TF·F... | BeFree | 25505176 | Detail |
| <0.001 | Squamous cell carcinoma of esophagus | Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squa... | BeFree | 25297082 | Detail |
| <0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | NA | BeFree | Detail | |
| <0.001 | Vascular Neoplasms | Triggering tissue factor (F3/TF) and thrombin receptors (F2R/PAR-1) may influenc... | BeFree | 25163932 | Detail |
| <0.001 | cervix carcinoma | NA | BeFree | Detail | |
| <0.001 | Restenosis | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma of colon | NA | BeFree | Detail | |
| <0.001 | intrahepatic cholangiocarcinoma | NA | BeFree | Detail | |
| <0.001 | Adenoma of lung | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of pancreas | NA | BeFree | Detail | |
| <0.001 | Nonorganic psychosis | NA | BeFree | Detail | |
| <0.001 | Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
| <0.001 | Human immunodeficiency virus, type 2 [HIV-2] infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
| <0.001 | Non-alcoholic Fatty Liver Disease | NA | BeFree | Detail | |
| <0.001 | lupus erythematosus | NA | BeFree | Detail | |
| <0.001 | Osteomalacia secondary to drug | NA | BeFree | Detail | |
| <0.001 | Langer mesomelic dysplasia syndrome | NA | BeFree | Detail | |
| <0.001 | Ichthyosis bullosa of Siemens | NA | BeFree | Detail | |
| <0.001 | endometrial carcinoma | NA | BeFree | Detail | |
| <0.001 | dementia | NA | BeFree | Detail | |
| 0.120 | Metabolic syndrome X | NA | BeFree,CTD_human | Detail | |
| <0.001 | Hepatitis C, Chronic | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of esophagus | Here, we used reverse transcription-PCR (RT-PCR) and western blot to detect prot... | BeFree | 25297082 | Detail |
| <0.001 | primary sclerosing cholangitis | NA | BeFree | Detail | |
| <0.001 | Osteosarcoma of bone | NA | BeFree | Detail | |
| 0.002 | Carcinogenesis | Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progres... | BeFree | 24469043 | Detail |
| <0.001 | Leukemogenesis | NA | BeFree | Detail | |
| <0.001 | Tumor Initiation | In the present study, male transgenic mice expressing human CAR and PXR were use... | BeFree | 24863967 | Detail |
| <0.001 | Tumor Initiation | Low PXR expression has been shown to promote tumor initiation and metastasis. | BeFree | 25268617 | Detail |
| 0.002 | hepatopulmonary syndrome | NA | GAD | Detail | |
| <0.001 | Epithelial ovarian cancer | NA | BeFree | Detail | |
| 0.007 | breast carcinoma | NA | BeFree | Detail | |
| 0.001 | Carcinoma of lung | A functional polymorphism in the 3'-UTR of PXR interacts with smoking to increas... | BeFree | 25268617 | Detail |
| 0.001 | Carcinoma of lung | Recently, PRR(L) was reported to enhance proliferation of breast and lung cancer... | BeFree | 26058814 | Detail |
| <0.001 | Secondary malignant neoplasm of lymph node | NA | BeFree | Detail | |
| 0.003 | colon carcinoma | NA | BeFree | Detail | |
| <0.001 | stomach carcinoma | NA | BeFree | Detail | |
| <0.001 | Carcinoma of bladder | NA | BeFree | Detail | |
| <0.001 | Central neuroblastoma | NA | BeFree | Detail | |
| <0.001 | acne | PAR-2 expression was increased in sebaceous glands of acne lesions. | BeFree | 25880702 | Detail |
| <0.001 | Malignant neoplasm of kidney | NA | BeFree | Detail | |
| <0.001 | Poorly differentiated carcinoma | Combined with clinical data, the expression of PAR1 in poorly differentiated (P=... | BeFree | 25297082 | Detail |
| <0.001 | Hyperalgesia, Thermal | NA | BeFree | Detail | |
| <0.001 | malignant pleural mesothelioma | Furthermore, we demonstrated a reduction of cell surface PAR1 expression in NCI-... | BeFree | 25364818 | Detail |
| <0.001 | Helicobacter pylori infection | PAR1 suppression of IRF5 and IL-12/23 secretion by macrophages provides a novel ... | BeFree | 24866378 | Detail |
| <0.001 | Diabetic Cardiomyopathies | NA | BeFree | Detail | |
| <0.001 | Endothelial dysfunction | NA | BeFree | Detail | |
| <0.001 | Cholestatic liver disease | NA | BeFree | Detail | |
| 0.122 | Drug-Induced Liver Injury | NA | CTD_human,GAD | Detail | |
| <0.001 | Rhinosinusitis | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of ovary | NA | BeFree | Detail | |
| <0.001 | Squamous cell carcinoma of the head and neck | NA | BeFree | Detail | |
| <0.001 | sarcoma | NA | BeFree | Detail | |
| <0.001 | Precursor B-cell lymphoblastic leukemia | NA | BeFree | Detail | |
| <0.001 | Partial Trisomy | NA | BeFree | Detail | |
| <0.001 | Liver regeneration disorder | Our results show that PPM1A can positively regulate PXR activity by counteractin... | BeFree | 25561723 | Detail |
| <0.001 | Asthma, Aspirin-Induced | NA | BeFree | Detail | |
| <0.001 | Chronic Cancer Pain | NA | BeFree | Detail | |
| <0.001 | Stage I Hepatocellular Carcinoma | NA | BeFree | Detail | |
| <0.001 | Epithelioma | NA | BeFree | Detail | |
| <0.001 | renal carcinoma | NA | BeFree | Detail | |
| 0.002 | hearing impairment | NA | GAD | Detail | |
| <0.001 | Cardiac fibrosis | NA | BeFree | Detail | |
| 0.006 | Mammary Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Hepatocarcinogenesis | NA | BeFree | Detail | |
| <0.001 | Tumor Angiogenesis | NA | BeFree | Detail | |
| <0.001 | Tumor Promotion | Phenobarbital-mediated tumor promotion in transgenic mice with humanized CAR and... | BeFree | 24863967 | Detail |
| 0.004 | colorectal cancer | NA | BeFree,GAD | Detail | |
| <0.001 | androgen independent prostate cancer | NA | BeFree | Detail | |
| <0.001 | Benign Prostatic Hyperplasia | NA | BeFree | Detail | |
| <0.001 | Non-Neoplastic Disorder | NA | BeFree | Detail | |
| 0.001 | Idiopathic Pulmonary Fibrosis | NA | BeFree | Detail | |
| <0.001 | uterine corpus cancer | NA | BeFree | Detail | |
| <0.001 | coronary artery disease | NA | BeFree | Detail | |
| 0.004 | liver carcinoma | This novel PXR isoform, displaying a dominant-negative activity and regulated by... | BeFree | 24798619 | Detail |
| 0.004 | liver carcinoma | For CYP3 family, the expression of PXR was decreased 60% in HCC, together with d... | BeFree | 25024626 | Detail |
| 0.004 | liver carcinoma | We have previously shown that PAR1 and PAR4 are able to promote the migration of... | BeFree | 25373316 | Detail |
| 0.004 | liver carcinoma | In a panel of HCC cell lines, PRR(L) generally promotes and PRR(S) suppresses pr... | BeFree | 26058814 | Detail |
| <0.001 | Allergic rhinitis (disorder) | NA | BeFree | Detail | |
| 0.002 | WARFARIN SENSITIVITY (disorder) | NA | GAD | Detail | |
| <0.001 | Steatohepatitis | NA | BeFree | Detail | |
| <0.001 | Mechanical Allodynia | PAR2 causes receptor-operated activation of TRPV4 channels and TRPV4 null mice h... | BeFree | 24779362 | Detail |
| <0.001 | Stage III Hepatocellular Carcinoma | NA | BeFree | Detail | |
| <0.001 | Idiopathic pulmonary arterial hypertension | NA | BeFree | Detail | |
| 0.003 | Adult Rickets | NA | LHGDN | Detail | |
| 0.002 | Hearing Loss | NA | GAD | Detail | |
| <0.001 | Acne Vulgaris | PAR-2 expression was increased in sebaceous glands of acne lesions. | BeFree | 25880702 | Detail |
| 0.121 | adenocarcinoma | NA | BeFree,CTD_human | Detail | |
| <0.001 | Alzheimer's disease | Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease mana... | BeFree | 25213397 | Detail |
| <0.001 | arteriosclerosis | NA | BeFree | Detail | |
| 0.002 | arthritis | NA | BeFree | Detail | |
| 0.002 | rheumatoid arthritis | NA | BeFree | Detail | |
| <0.001 | asthma | NA | BeFree | Detail | |
| <0.001 | atherosclerosis | NA | BeFree | Detail | |
| <0.001 | Autoimmune Diseases | TLR2, a PRR, recognizes exogenous PAMPs, and endogenous damage-associated molecu... | BeFree | 26079624 | Detail |
| 0.120 | Barrett esophagus | NA | CTD_human | Detail | |
| <0.001 | Malignant neoplasm of urinary bladder | NA | BeFree | Detail | |
| <0.001 | Bone Marrow Diseases | NA | BeFree | Detail | |
| 0.014 | Malignant neoplasm of breast | NA | BeFree,GAD | Detail | |
| <0.001 | candidiasis | NA | BeFree | Detail | |
| <0.001 | Candidiasis, Chronic Mucocutaneous | NA | BeFree | Detail | |
| 0.003 | Malignant tumor of colon | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of endometrium | NA | BeFree | Detail | |
| <0.001 | female breast carcinoma | NA | BeFree | Detail | |
| <0.001 | renal cell carcinoma | NA | BeFree | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| PAR-2 was immunolocalized in oral SCC and carcinoma in situ cells, especially in those on the periph... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The in vivo experiments using PXR siRNA revealed that Tan IIA could protect against LCA-induced hepa... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In UC, pancolitis (but not exclusively left-sided colitis) was associated with altered expression of... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Here, we used reverse transcription-PCR (RT-PCR) and western blot to detect protease-activated recep... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Artemisinin protects against dextran sulfate-sodium-induced inflammatory bowel disease, which is ass... | DisGeNET | Detail |
| Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activa... | DisGeNET | Detail |
| Genomic DNA from 2823 individuals of Caucasian origin including 859 patients with Crohn's disease (C... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Hence, agonists for PXR, RAR and RXR may be potentially used to improve the efficacy of imatinib in ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Coagulation pathway sensors (F3/TF, F2R/PAR-1) are expressed in MB in a subtype-specific manner, and... | DisGeNET | Detail |
| The role of PAR1 in mesothelioma progression is just emerging and our observations can promote furth... | DisGeNET | Detail |
| Nuclear hormone receptors PXR and CAR and metabolic diseases. | DisGeNET | Detail |
| Overall, our results uncover SLC13A5 as a novel target gene of PXR and may contribute to drug-induce... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Research undertaken over the last decade has uncovered critical roles of CD5L as a PRR of bacterial ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Low PXR expression has been shown to promote tumor initiation and metastasis. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro ... | DisGeNET | Detail |
| PAR-2 activation may modulate these responses through adenosine triphosphate (ATP) release, which is... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Regarding TE-1 and TE-10 protein expression, we found that in randomized esophageal carcinoma, PAR1 ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| A functional polymorphism in the 3'-UTR of PXR interacts with smoking to increase lung cancer risk i... | DisGeNET | Detail |
| Recently, PRR(L) was reported to enhance proliferation of breast and lung cancer cells. | DisGeNET | Detail |
| The purpose of this study was to identify interacting signaling pathways by which the activation of ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The present finding uncovers a novel role of MDA-9/syntenin as an important TF·FVIIa·Xa/PAR-1-regula... | DisGeNET | Detail |
| Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Triggering tissue factor (F3/TF) and thrombin receptors (F2R/PAR-1) may influence the vascular tumor... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Here, we used reverse transcription-PCR (RT-PCR) and western blot to detect protease-activated recep... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiatio... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In the present study, male transgenic mice expressing human CAR and PXR were used to detect possible... | DisGeNET | Detail |
| Low PXR expression has been shown to promote tumor initiation and metastasis. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| A functional polymorphism in the 3'-UTR of PXR interacts with smoking to increase lung cancer risk i... | DisGeNET | Detail |
| Recently, PRR(L) was reported to enhance proliferation of breast and lung cancer cells. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| PAR-2 expression was increased in sebaceous glands of acne lesions. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Combined with clinical data, the expression of PAR1 in poorly differentiated (P=0.016) and middle an... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Furthermore, we demonstrated a reduction of cell surface PAR1 expression in NCI-H28 and malignant pl... | DisGeNET | Detail |
| PAR1 suppression of IRF5 and IL-12/23 secretion by macrophages provides a novel mechanism by which t... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Our results show that PPM1A can positively regulate PXR activity by counteracting PXR inhibitory sig... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Phenobarbital-mediated tumor promotion in transgenic mice with humanized CAR and PXR. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| This novel PXR isoform, displaying a dominant-negative activity and regulated by DNA methylation, is... | DisGeNET | Detail |
| For CYP3 family, the expression of PXR was decreased 60% in HCC, together with decreases in CYP3A4, ... | DisGeNET | Detail |
| We have previously shown that PAR1 and PAR4 are able to promote the migration of hepatocellular carc... | DisGeNET | Detail |
| In a panel of HCC cell lines, PRR(L) generally promotes and PRR(S) suppresses proliferation, migrati... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| PAR2 causes receptor-operated activation of TRPV4 channels and TRPV4 null mice have attenuated PAR2-... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| PAR-2 expression was increased in sebaceous glands of acne lesions. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TLR2, a PRR, recognizes exogenous PAMPs, and endogenous damage-associated molecular patterns and has... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs386525803 dbSNP
- Genome
- hg19
- Position
- chr3:119,499,331-119,537,334
- Variant Type
- snv
Genome browser